For a patient with end-stage renal disease, the gap between a matched donor kidney and a successful transplant is measured in hours. Cold storage on ice, the workhorse method for decades, gives surgeons a narrow window before ischemic injury starts to compromise the graft. BMI OrganBank, a seed-stage medical device company in Winston-Salem, North Carolina, is trying to widen that window. The company has secured FDA Breakthrough Device Designation for a portable kidney preservation device co-developed with transplant surgeons, and is preparing to begin clinical studies [BMI OrganBank].
The patient population here is significant and underserved. More than 90,000 Americans sit on the kidney transplant waitlist at any given time, and a meaningful share of recovered organs are never transplanted, often because logistics and preservation windows do not line up with a viable recipient. The standard of care today remains static cold storage. Hypothermic machine perfusion is increasingly used for higher-risk kidneys and has clinical evidence supporting reduced delayed graft function, but adoption is uneven and the devices are not universally portable.
The bet
BMI OrganBank is building a portfolio of perfusion-based devices. Its flagship is the OrganBank Transport device, co-developed with Duke University's DEVOL lab [BMI OrganBank]. A separate portable OrganBank kidney device, co-developed with transplant surgeons, is the program that received FDA Breakthrough Device Designation [BMI OrganBank]. The underlying perfusion technology is licensed from the Duke Ex-Vivo Organ Lab, led by Drs. Andrew S. Barbas and Matthew Hartwig [BMI OrganBank]. The proprietary OrganBank organ preservation system is currently moving through the FDA clearance process [BMI OrganBank].
The customer in this market is the organ procurement organization (OPO) and the transplant center. Both are under sustained pressure to reduce discard rates and to expand the geographic radius of viable matches.
Why it could matter
Breakthrough Device Designation gives the company more frequent FDA interaction and the potential for prioritized review. The category itself has institutional momentum: federal scrutiny of OPO performance has intensified, and the transplant community is actively looking for tools that increase organ utilization [BMI OrganBank].
BMI OrganBank's funding profile includes a $600,000 seed round and a $3,500,000 grant, with the National Institutes of Health among the named backers [Crunchbase]. The company has also been selected by the North Carolina Biotechnology Center for funding [BMI OrganBank].
| Metric | Value |
|---|---|
| NIH-associated grant | $3.5M |
| Seed round | $0.6M |
Non-dilutive funding is a sensible match for a device company at this stage: it extends runway through preclinical and early clinical work without forcing a premature valuation conversation.
The team
Co-founder and CEO Carrie DiMarzio led the development and FDA Emergency Use Authorization of the SuppleVent ventilator, and is now steering the OrganBank system through FDA clearance [BMI OrganBank]. Co-founder George Barr brings more than four decades of work in advanced medical technologies [BMI OrganBank]. Robert Neusner serves as President and COO, with Josh Copus, PhD, and Tyler Adcock among the broader team [BMI OrganBank]. The company also recently announced a strategic partnership with Dedicated Staffing Solutions [PR Newswire].
What bears say, and what bulls answer
The most credible concern is execution risk. The kidney device has Breakthrough Designation but has not yet completed the clinical studies that would support a marketing authorization. Skeptics will note that the path from a Duke-licensed technology and a designation letter to a commercially adopted device is long and capital-intensive. The bull answer is structural: kidney is the highest-volume solid organ transplant, the device has academic surgical co-development baked in from the start through the Duke collaboration [BMI OrganBank], and the regulatory designation should compress the FDA timeline if early clinical data hold.
What to watch
The next twelve months should clarify a great deal. The two milestones that matter most are the start of clinical studies for the portable kidney device and the trajectory of the FDA clearance process for the OrganBank preservation system [BMI OrganBank]. A priced Series A, the first named OPO or transplant center customer, and any peer-reviewed preclinical data from the Duke collaboration would each meaningfully de-risk the story.